{"id":"parecoxib-sodium-valdecoxib","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Edema"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Cardiovascular events (thromboembolic)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Parecoxib is the intravenous prodrug of valdecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor. By selectively blocking COX-2, it reduces the production of pro-inflammatory prostaglandins while sparing COX-1-mediated protective effects in the gastrointestinal tract and platelets. This selectivity provides pain relief and anti-inflammatory benefits with a potentially improved gastrointestinal safety profile compared to non-selective NSAIDs.","oneSentence":"Parecoxib sodium is a selective COX-2 inhibitor that reduces prostaglandin production to provide anti-inflammatory and analgesic effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:59:57.569Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute postoperative pain"},{"name":"Rheumatoid arthritis"},{"name":"Osteoarthritis"}]},"trialDetails":[{"nctId":"NCT03915561","phase":"PHASE2","title":"Effect of Intravenous Dynastat on Postoperative Sore Throat","status":"UNKNOWN","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2019-03-01","conditions":"Sore Throat, Postoperative Complications","enrollment":140},{"nctId":"NCT01221025","phase":"PHASE4","title":"Effect Study of Parecoxib to Treat Emergence Delirium and Postoperative Pain","status":"UNKNOWN","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2010-09","conditions":"Emergence Delirium, Postoperative Pain","enrollment":900},{"nctId":"NCT00651300","phase":"PHASE3","title":"A Study of the Recovery Benefits After Treatment With Parecoxib/Valdecoxib in Patients Undergoing Abdominal Surgery","status":"TERMINATED","sponsor":"Pfizer","startDate":"2003-04","conditions":"Pain","enrollment":91},{"nctId":"NCT00636064","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Valdecoxib Plus Parecoxib Versus Valdecoxib Plus Placebo for the Treatment of Pain After Coronary Artery Bypass Surgery","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-01","conditions":"Pain","enrollment":1671}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":110,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Parecoxib Sodium/Valdecoxib","genericName":"Parecoxib Sodium/Valdecoxib","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Parecoxib sodium is a selective COX-2 inhibitor that reduces prostaglandin production to provide anti-inflammatory and analgesic effects. Used for Acute postoperative pain, Rheumatoid arthritis, Osteoarthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}